Back to Trial

Oracle Runs

Oracle findings and outcome history for Study With Phage for CF Subjects With Pseudomonas Lung Infection (NCT06998043).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:51 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Sponsor publicly discontinued this exact Phase 2b BX004 CF trial after internal analysis and DMC feedback tied to unexpectedly high adverse-event rates. Subsequent SEC filing confirms BX004 development was discontinued. That is a clearly negative trial-specific public readout, not a positive efficacy outcome.

Sources
Sponsorbiospace.com12/8/25
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

BiomX said it discontinued the ongoing Phase 2b BX004 CF trial after DMC feedback and internal analysis of unexpectedly high adverse-event rates.

View source
Web Searchsec.gov3/31/26
BiomX Inc. Annual Report on Form 10-K for year ended December 31, 2025

The 10-K states that in December 2025 BiomX discontinued development of BX004 following internal analysis and DMC feedback related to adverse events in trial participants.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Sponsor publicly discontinued this exact Phase 2b BX004 CF trial after internal analysis and DMC feedback tied to unexpectedly high adverse-event rates. Subsequent SEC filing confirms BX004 development was discontinued. That is a clearly negative trial-specific public readout, not a positive efficacy outcome.

Found Apr 1, 2026, 7:51 PMOutcome date Dec 8, 2025, 12:00 AMReviewed Apr 1, 2026, 7:56 PM
Sponsorbiospace.comDec 8, 2025, 12:00 AM
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
BiomX said it discontinued the ongoing Phase 2b BX004 CF trial after DMC feedback and internal analysis of unexpectedly high adverse-event rates.
Web Searchsec.govMar 31, 2026, 12:00 AM
BiomX Inc. Annual Report on Form 10-K for year ended December 31, 2025
The 10-K states that in December 2025 BiomX discontinued development of BX004 following internal analysis and DMC feedback related to adverse events in trial participants.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:56 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)95% confidenceReviewed Apr 1, 2026, 7:56 PM

Sponsor publicly discontinued this exact Phase 2b BX004 CF trial after internal analysis and DMC feedback tied to unexpectedly high adverse-event rates. Subsequent SEC filing confirms BX004 development was discontinued. That is a clearly negative trial-specific public readout, not a positive efficacy outcome.